TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7618660

Group type: EXPERIMENTAL
Intervention: Thiopentone 5 mg.kg‐1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg.kg‐1
Number of subjects: 9
Study: 2211767

Group type: EXPERIMENTAL
Intervention: Keller's arthroplasty
Number of subjects: 81

Group type: COMPARATOR
Intervention: Arthrodesis
Number of subjects: 81
Study: 659115

Group type: EXPERIMENTAL
Intervention: Kallikrein (Padutin 100)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 30585111

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 60
Study: 29016479

Group type: EXPERIMENTAL
Intervention: Foam Rolling (20 minutes of FR exercises on quadriceps, hamstrings, adductors, gluteals, and gastrocnemius)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Passive Recovery (20 minutes sit on a bench)
Number of subjects: 18
Study: 28615651

Group type: EXPERIMENTAL
Intervention: D‐MCT (Metacognitive Training for Depression)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Active control intervention
Number of subjects: 84
Study: 26360975

Group type: EXPERIMENTAL
Intervention: Wii Fit balance training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional exercise
Number of subjects: 60
Study: 23905568

Group type: EXPERIMENTAL
Intervention: Rehabilitation clinic (RC)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (discharged in 2008)
Number of subjects: 19
Study: 21448197

Group type: EXPERIMENTAL
Intervention: Darbepoetin (10 μg kg(‐1) subcutaneously)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no darbepoetin)
Number of subjects: 20
Study: 19228402

Group type: EXPERIMENTAL
Intervention: 12 weeks of a twice‐weekly 90‐minute yoga class
Number of subjects: 59

Group type: COMPARATOR
Intervention: Waiting list for yoga classes
Number of subjects: 59
Study: 17710014

Group type: EXPERIMENTAL
Intervention: Multidisciplinary prevention program
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Exercise prevention program
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 162
Study: 15001682

Group type: EXPERIMENTAL
Intervention: Cold pressor testing (CPT)
Number of subjects: 56
Study: 11553000

Group type: EXPERIMENTAL
Intervention: G‐CSF‐mobilized peripheral blood stem cell (PBSC) grafts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: G‐CSF mobilization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bone marrow (BM) grafts
Number of subjects: 0
Study: 9559614

Group type: EXPERIMENTAL
Intervention: Filgrastim 75 microg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Filgrastim 300 microg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 7934737

Group type: EXPERIMENTAL
Intervention: Questionnaire submitted immediately after Clinical Psychiatry examination (224 students)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Questionnaire mailed (66 students)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Female students
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Students considering psychiatry as a specialization
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Medical students
Number of subjects: 290
Study: 3148180

Group type: EXPERIMENTAL
Intervention: bupranolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 29588861

Group type: EXPERIMENTAL
Intervention: Functional standing frame programme (prolonged standing and repeated sit to stand)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual physiotherapy
Number of subjects: 50
Study: 28571470

Group type: EXPERIMENTAL
Intervention: Non-subsampled Contourlet transform (NSCT) combined with nonlinear enhancement function
Number of subjects: 0

Group type: COMPARATOR
Intervention: CT method (Control)
Number of subjects: 0
Study: 26337688

Group type: EXPERIMENTAL
Intervention: Multimodal intervention combining biological, cognitive behavioral, and psychophysiological techniques
Number of subjects: 714

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 714
Study: 23999933

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg daily for 104 weeks
Number of subjects: 613

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study: 20970213

Group type: EXPERIMENTAL
Intervention: Transfusion with packed red blood cells
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: High Hb levels
Number of subjects: 414

Group type: COMPARATOR
Intervention: Low Hb no transfusion
Number of subjects: 414
Study: 18490229

Group type: EXPERIMENTAL
Intervention: Preterax (perindopril 2 mg and indapamide 0.625 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cilazapril (2.5 mg)
Number of subjects: 41
Study: 16554495

Group type: EXPERIMENTAL
Intervention: Hippocampal electrical stimulation (90 microsec, 190 Hz)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Hippocampal electrical stimulation OFF period
Number of subjects: 4

Group type: COMPARATOR
Intervention: Baseline period
Number of subjects: 4
Study: 15297776

Group type: EXPERIMENTAL
Intervention: Adsorptive granulocyte/monocyte apheresis (GMA) with up to 11 sessions over 10 weeks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Prednisolone (PSL) increased to 30 mg/day/patient
Number of subjects: 69
Study: 11738312

Group type: EXPERIMENTAL
Intervention: Surgical closure
Number of subjects: 521

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 521
Study: 9407412

Group type: EXPERIMENTAL
Intervention: Proteinuria (measured by urine dipstick determinations)
Number of subjects: 12866

Group type: EXPERIMENTAL
Intervention: Higher and more persistent proteinuria
Number of subjects: 12866
Study: 8136096

Group type: EXPERIMENTAL
Intervention: Continue HDFP medication
Number of subjects: 431

Group type: COMPARATOR
Intervention: Discontinue medication with no dietary intervention
Number of subjects: 431

Group type: COMPARATOR
Intervention: Discontinue medication with sodium restriction and potassium increase
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Weight reduction intervention for overweight patients
Number of subjects: 431

Group type: COMPARATOR
Intervention: Withdrawn from diuretic alone
Number of subjects: 431

Group type: COMPARATOR
Intervention: Withdrawn from both diuretic plus reserpine
Number of subjects: 431
Study: 3619842

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 4 mg every 6 h for 48 h before and after altitude exposure
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29668691

Group type: EXPERIMENTAL
Intervention: Routine Data Quality Assessments (RDQAs)
Number of subjects: 27
Study: 29328639

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (0.2 mL of 0.8% gel)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid + aminocaproic acid (2 mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alvogyl® (an anesthetic and antiseptic paste)
Number of subjects: 60
Study: 23981570

Group type: EXPERIMENTAL
Intervention: Aroma exposure time of 18 seconds and high concentration (5 ×)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Aroma exposure time of 3 seconds and high concentration (5 ×)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Aroma exposure time of 18 seconds and low concentration (not specified)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Aroma exposure time of 3 seconds and low concentration (not specified)
Number of subjects: 38
Study: 22948448

Group type: EXPERIMENTAL
Intervention: Female athletes
Number of subjects: 149

Group type: COMPARATOR
Intervention: Female nonathletes
Number of subjects: 149
Study: 21115926

Group type: EXPERIMENTAL
Intervention: Carboplatin (CBDCA) AUC 3 and Paclitaxel (PTX) 90 mg/m² (PCb arm)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Carboplatin (CBDCA) AUC 3 plus Gemcitabine (GEM) 1000 mg/m² (GCb arm)
Number of subjects: 75
Study: 19049301

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/timolol 0.5%
Number of subjects: 94

Group type: COMPARATOR
Intervention: Dorzolamide 2%/timolol 0.5%
Number of subjects: 94
Study: 16805934

Group type: EXPERIMENTAL
Intervention: 400 mg of gabapentin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 800 mg of gabapentin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 12391112

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nonexercise session (Control)
Number of subjects: 8
Study: 10450387

Group type: EXPERIMENTAL
Intervention: Multipurpose disinfecting solution
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: One-step hydrogen peroxide
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: One-step hydrogen peroxide and multipurpose solutions
Number of subjects: 150
Study: 7480237

Group type: EXPERIMENTAL
Intervention: Azithromycin (single oral dose taken at 8 P.M. the day before surgery)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 339
Study: 2507125

Group type: EXPERIMENTAL
Intervention: LC9018 with radiation therapy
Number of subjects: 61
Study: 4854116

Group type: EXPERIMENTAL
Intervention: Whole blood replacement
Number of subjects: 27

Group type: COMPARATOR
Intervention: Plasma replacement
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dextran 75 replacement
Number of subjects: 27
Study: 31308312

Group type: EXPERIMENTAL
Intervention: Modified Thompson procedure (Group 2)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Original Thompson procedure (Group 1)
Number of subjects: 26
Study: 28621047

Group type: EXPERIMENTAL
Intervention: PCR group (27 women)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard treatment group (27 women)
Number of subjects: 54
Study: 26450544

Group type: EXPERIMENTAL
Intervention: Psychological support for caregivers (Group 1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 48
Study: 23588866

Group type: EXPERIMENTAL
Intervention: Patient controlled epidural bolus (HKEB)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Continuous epidural infusion (SEI)
Number of subjects: 45
Study: 21473826

Group type: EXPERIMENTAL
Intervention: Expiration holding group
Number of subjects: 12

Group type: COMPARATOR
Intervention: Automatic measurement group
Number of subjects: 12
Study: 18505746

Group type: EXPERIMENTAL
Intervention: Supervised treadmill walking training
Number of subjects: 11

Group type: COMPARATOR
Intervention: Non-exercise control stage
Number of subjects: 11
Study: 17197845

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 32
Study: 15114090

Group type: EXPERIMENTAL
Intervention: CI-sparing regimen (sirolimus + reduced dose tacrolimus)
Number of subjects: 70

Group type: COMPARATOR
Intervention: CI-free regimen (sirolimus + mycophenolate mofetil)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CI-sparing regimen
Number of subjects: 70

Group type: COMPARATOR
Intervention: CI-free regimen
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 70
Study: 11602544

Group type: EXPERIMENTAL
Intervention: Intravenous dofetilide (6, 9, and 15 microgram/kg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intravenous dofetilide (1.5 and 3 microgram/kg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intravenous dofetilide
Number of subjects: 51
Study: 9534677

Group type: EXPERIMENTAL
Intervention: Intradermal hepatitis B vaccine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intramuscular hepatitis B vaccine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Delayed type hypersensitivity (DTH) test
Number of subjects: 42
Study: 7996804

Group type: EXPERIMENTAL
Intervention: High flux polysulfone (HF-PS) membranes
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low flux polymethylmethacrylate (LF-PMMA) membranes
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cellulosic (cuprophane-CU) membranes
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High flux polysulfone (HF-PS) membranes (sixth reuse)
Number of subjects: 9
Study: 3455953

Group type: EXPERIMENTAL
Intervention: Diazepam (0.6 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sodium chloride (control)
Number of subjects: 12
Study: 29112625

Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC)
Number of subjects: 13

Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 13
Study: 27000105

Group type: EXPERIMENTAL
Intervention: Ambulatory glucose profile (continuous glucose monitoring)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Capillary glucose testing (control)
Number of subjects: 87
Study: 24305063

Group type: EXPERIMENTAL
Intervention: 25 mg testosterone enanthate
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 50 mg testosterone enanthate
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 125 mg testosterone enanthate
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 300 mg testosterone enanthate
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 600 mg testosterone enanthate
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (no testosterone)
Number of subjects: 121
Study: 22440993

Group type: EXPERIMENTAL
Intervention: Inpatient Diabetes Management Program (IDMP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual education only (non-IDMP group)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 20464814

Group type: EXPERIMENTAL
Intervention: Breathing 14.1% oxygen (hypoxia) at low photopic (28 cd x m(‐2)), borderline upper mesopic (approximately 2.1 cd x m(‐2)), and midmesopic (approximately 0.26 cd x m(‐2)) luminance
Number of subjects: 12

Group type: COMPARATOR
Intervention: Breathing air at sea level (normoxia) at low photopic (28 cd x m(‐2)), borderline upper mesopic (approximately 2.1 cd x m(‐2)), and midmesopic (approximately 0.26 cd x m(‐2)) luminance
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Breathing 100% oxygen (hyperoxia) at mesopic luminance
Number of subjects: 12
Study: 18639360

Group type: EXPERIMENTAL
Intervention: Bilateral Arm Training with Rhythmic Auditory Cueing (BATRAC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Dose Matched Therapeutic Exercises (DMTE)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: BATRAC
Number of subjects: 18

Group type: COMPARATOR
Intervention: DMTE
Number of subjects: 18
Study: 17919964

Group type: EXPERIMENTAL
Intervention: Bridging social capital (contact amongst local friends)
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: Bonding social capital (attachment to neighbourhood)
Number of subjects: 9000
Study: 15196721

Group type: EXPERIMENTAL
Intervention: Laser-assisted ICSI
Number of subjects: 280

Group type: COMPARATOR
Intervention: Conventional ICSI
Number of subjects: 280
Study: 11739462

Group type: EXPERIMENTAL
Intervention: E2 supplementation (1 mg micronized 17 beta‐E2 orally twice daily for 6‐23 days)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: E2 supplementation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 9
Study: 9241570

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg o.d.) + Pindolol (2.5 mg t.d.s.)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg or 40 mg) after the trial
Number of subjects: 54

Group type: COMPARATOR
Intervention: Paroxetine (20 mg o.d.) + Placebo
Number of subjects: 54
Study: 8309737

Group type: EXPERIMENTAL
Intervention: Bedside pulmonary mechanics testing (PM)
Number of subjects: 468
Study: 3789294

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31728894

Group type: EXPERIMENTAL
Intervention: PreView intervention
Number of subjects: 508

Group type: COMPARATOR
Intervention: Control group (video about healthy lifestyle)
Number of subjects: 508
Study: 30543803

Group type: EXPERIMENTAL
Intervention: ParticiPAte CP (8-week goal-directed, individualized, participation-focused therapy delivered by a physical therapist)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: ParticiPAte CP
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual care (waitlist control)
Number of subjects: 37
Study: 28089468

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (Normal Saline)
Number of subjects: 101
Study: 23609832

Group type: EXPERIMENTAL
Intervention: Classic Ponzo illusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified right Ponzo illusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified left Ponzo illusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canonical illusion vs. modified right illusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single case analysis in neglect group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition with parallel lines
Number of subjects: 0
Study: 21311746

Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS) to the anterior temporal lobes (ATL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: sham stimulation (control)
Number of subjects: 60
Study: 19554657

Group type: EXPERIMENTAL
Intervention: Sodium phosphate plus 240 mg of tablet simethicone
Number of subjects: 124

Group type: COMPARATOR
Intervention: Sodium phosphate plus placebo
Number of subjects: 124
Study: 16773549

Group type: EXPERIMENTAL
Intervention: DMP participants
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DMP participants (younger than 70 years)
Number of subjects: 20
Study: 15586301

Group type: EXPERIMENTAL
Intervention: Mepivacaine 4% with 0.1 mg of morphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mepivacaine 4% with saline (placebo)
Number of subjects: 40
Study: 11141143

Group type: EXPERIMENTAL
Intervention: Known diabetes
Number of subjects: 4662

Group type: EXPERIMENTAL
Intervention: HbA(1c) concentration
Number of subjects: 4662

Group type: EXPERIMENTAL
Intervention: HbA(1c) concentration >/=5%
Number of subjects: 4662

Group type: COMPARATOR
Intervention: Men with known diabetes excluded
Number of subjects: 4662
Study: 8989179

Group type: EXPERIMENTAL
Intervention: Vecuronium infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 18
Study: 8480475

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 10
Study: 2979673

Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pirenzepine 100 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pirenzepine 150 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propantheline 15 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propantheline 45 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 10
Study: 31053513

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1600 IU/day vitamin D3)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 28279085

Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - Aquatic activities 3 times a week from weeks 10-12 to 38-39 of gestation
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control Group (CG) - No aquatic activities
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 111
Study: 29741823

Group type: EXPERIMENTAL
Intervention: Prednisolone alone
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Thalidomide alone
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Prednisolone plus Clofazimine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Prednisolone plus Thalidomide
Number of subjects: 66
Study: 23686894

Group type: EXPERIMENTAL
Intervention: Vaccinium arctostaphylos fruit hydroalcoholic extract (350 mg capsule every 8 hours for 2 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 22234907

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU every four months for 16 months)
Number of subjects: 2378

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2378
Study: 20019589

Group type: EXPERIMENTAL
Intervention: Clopidogrel Leti 75 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel Sanofi (Plavix) 75 mg
Number of subjects: 0
Study: 18667923

Group type: EXPERIMENTAL
Intervention: Suppressive acyclovir therapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 16313110

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba leaf extract (EGB) 9.6 mg orally, three times per day for three months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional therapy only (Control group)
Number of subjects: 68
Study: 11875324

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30 mg
Number of subjects: 151

Group type: COMPARATOR
Intervention: Amiloride 2.5 + Hydrochlorothiazide 5 mg
Number of subjects: 151
Study: 10592130

Group type: EXPERIMENTAL
Intervention: Children with PKU
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal children
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Children with PKU <7 years
Number of subjects: 42
Study: 8652949

Group type: EXPERIMENTAL
Intervention: Early re-feeding (breast feeding resumed or early re-feeding in non-breast-fed infants within 2-3 days)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Late re-feeding (return to original feeding pattern after 4-6 days)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Early re-feeding
Number of subjects: 122
Study: 2360135

Group type: EXPERIMENTAL
Intervention: Cefotetan 0.5 g
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Cefotetan 1.0 g
Number of subjects: 172

Group type: COMPARATOR
Intervention: Ceftriaxone 0.25 g
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: All groups (Cefotetan 0.5 g, Cefotetan 1.0 g, Ceftriaxone 0.25 g)
Number of subjects: 172
Study: 695661

Group type: EXPERIMENTAL
Intervention: Prophylactic gestagen therapy
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Prophylactic gestagen therapy initiated at the first missed period or later
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Prophylactic gestagen therapy in the immediate post-ovulatory phase
Number of subjects: 451

Group type: COMPARATOR
Intervention: Overall pregnancies without gestagen therapy
Number of subjects: 451